Diet Pills Global Market Report 2024

The diet pills market has grown rapidly in recent years. It will grow from $1.62 billion in 2023 to $1.81 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth observed during the historic period can be attributed to various factors, including increased awareness of health and fitness, rising obesity rates, changes in lifestyles and dietary patterns, effective marketing and promotion strategies, and medical endorsements and prescriptions.

The diet pills market is expected to see rapid growth in the next few years. It will grow to $2.79 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to a sustained focus on health and wellness, a global increase in the overweight population, the expansion of weight management services, innovations in formulations and ingredients, and the growing prevalence of e-commerce and direct-to-consumer channels. Major trends expected in the forecast period include technological innovations in formulations, an emphasis on mental well-being, the incorporation of appetite suppressants, the integration of digital health solutions, and the expansion of online and e-commerce distribution channels.

The escalating issue of obesity is anticipated to drive the growth of the diet pill market in the future. Obesity, characterized by abnormal or excessive weight gain, typically with a body mass index (BMI) exceeding 30, poses significant health risks. It increases the likelihood of various cancers, including those affecting the esophagus, colon, rectum, liver, gallbladder, pancreas, and kidneys. Additionally, obesity is associated with the development of disorders such as type 2 diabetes (T2D) and cardiovascular diseases (CVD). Individuals struggling with obesity often turn to diet pills as a form of medication to aid in weight loss by reducing appetite and food cravings. For instance, as of May 2022, data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) revealed that more than 2 in 5 adults (42.4%) have obesity, with approximately 1 in 11 adults (9.2%) experiencing severe obesity. Consequently, the increasing prevalence of obesity is a significant driver for the growth of the diet pill market.

The implementation of various initiatives is expected to contribute to the growth of the diet pills market. Initiatives involve specific actions, projects, or programs undertaken to achieve particular goals or address specific issues. One example is the initiative taken by Currax Pharmaceuticals LLC, a US-based specialty biopharmaceutical company and the manufacturer of the oral weight loss medication brand CONTRAVE (naltrexone HCl/bupropion HCl). In August 2022, the company launched a new campaign called "One Size Does Not Fit All," aiming to highlight the unique challenges faced by individuals dealing with overweight or obesity. The campaign emphasizes the necessity of a personalized approach to weight loss for long-term success. Therefore, the increasing adoption of initiatives is a driving force behind the growth of the diet pills market.

The increasing prevalence of chronic diseases is expected to drive the growth of the diet pills market. Chronic diseases, characterized by conditions or illnesses that last for more than a year and require ongoing medical treatment, necessitate comprehensive management approaches. These approaches often involve lifestyle modifications, such as adopting a balanced diet, engaging in regular physical activity, and making behavioral changes. As of January 2023, data from the National Library of Medicine, a US-based agency, suggests that the number of people in the US aged 50 and older with at least one chronic condition is projected to increase to 142.66 million by 2050. The rising prevalence of chronic diseases will consequently contribute to the growth of the diet pills market.

The popularity of plant-based supplements emerges as a key trend in the diet pill market, with companies developing plant-based diet pills to maintain their market positions. For instance, in April 2022, Wellbeing Nutrition, an India-based plant-based nutrition company, launched SLOW, a formulation consisting of 13 supplements catering to various health and wellness needs, including reproductive support, bone health, weight loss, and daily multivitamins. The SLOW technology employs continuous-release coated pellets in a capsule to ensure the timely digestion of vitamins and nutrients throughout the day. This new line is designed to meet consumer demands for increased energy, physical endurance, mental alertness, and functional health benefits for disease prevention.

In November 2022, Audax Private Equity, a US-based middle-market investment company, acquired Medi-Weightloss, Inc. for an undisclosed amount. Through this acquisition, Medi-Weightloss expanded access to care for an underserved and growing patient population. Medi-Weightloss is a US-based company that provides specialized weight-loss programs addressing obesity and associated ailments, including the provision of weight loss and diet pills.

Major companies operating in the diet pills market report are GlaxoSmithKline plc, Iovate Health Sciences International Inc., Novo Nordisk A/S, Gelesis Inc., VIVUS Inc., Pfizer Inc., Zoller India Pvt. Ltd., Creative Biosciences Pvt. Ltd., Applied Nutrition Ltd. (India), Herbalife Nutrition India Private Limited, Camillotek India Pvt. Ltd., Avon Products Inc., NOW Foods, MuscleTech Research and Development LLC, Healthviva Group of Companies, Nalpropion Pharmaceuticals LLC, Chong's Health Care Pte. Ltd., Currax Pharmaceuticals LLC, TEVA PHARMACEUTICAL INDUSTRIES Ltd., Eli Lilly and Company, Arena Pharmaceuticals GmbH & Co. KG, Orexigen Therapeutics Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Roche Holding AG, Sanofi SA, Boehringer Ingelheim International GmbH, Merck & Co. Inc., Johnson & Johnson, Abbott Laboratories.

North America was the largest region in the diet pills market in 2023. The regions covered in the diet pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diet pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of diet pill products include prescription, over-the-counter, and herbal supplements. A prescription is a written authorization from a doctor for access to a medication that cannot be obtained without such approval. Prescription diet pills are typically recommended by healthcare professionals due to the potential risks and dangers associated with misuse or abuse of these medications. These pills are utilized by teenagers and adults and are available through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. They are applied for purposes such as appetite suppression, fat blocking, and other weight management objectives.

The diet pills market research report provides diet pills market statistics, including diet pills industry global market size, regional shares, competitors with a diet pills market share, detailed diet pills market segments, market trends and opportunities, and any further data you may need to thrive in the diet pills industry. This diet pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diet pills market consists of sales of xenical, qsymia, saxenda, diethylpropion, liraglutide, and phentermine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.